These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 17214606)

  • 1. Metabolic drug interactions with newer antipsychotics: a comparative review.
    Spina E; de Leon J
    Basic Clin Pharmacol Toxicol; 2007 Jan; 100(1):4-22. PubMed ID: 17214606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer antipsychotics: comparative review of drug interactions.
    Spina E; Scordo MG
    Expert Rev Neurother; 2001 Nov; 1(2):171-82. PubMed ID: 19811029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and drug interactions: update for new antipsychotics.
    Ereshefsky L
    J Clin Psychiatry; 1996; 57 Suppl 11():12-25. PubMed ID: 8941167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.
    Caccia S
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1073-80. PubMed ID: 12186270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
    Murray M
    J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformation of post-clozapine antipsychotics: pharmacological implications.
    Caccia S
    Clin Pharmacokinet; 2000 May; 38(5):393-414. PubMed ID: 10843459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.
    Urichuk L; Prior TI; Dursun S; Baker G
    Curr Drug Metab; 2008 Jun; 9(5):410-8. PubMed ID: 18537577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between the cytochrome P450 system and the second-generation antipsychotics.
    Prior TI; Baker GB
    J Psychiatry Neurosci; 2003 Mar; 28(2):99-112. PubMed ID: 12670127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic drug interactions with new psychotropic agents.
    Spina E; Scordo MG; D'Arrigo C
    Fundam Clin Pharmacol; 2003 Oct; 17(5):517-38. PubMed ID: 14703714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug metabolism and atypical antipsychotics.
    Prior TI; Chue PS; Tibbo P; Baker GB
    Eur Neuropsychopharmacol; 1999 Jun; 9(4):301-9. PubMed ID: 10422890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia.
    Vohora D
    Curr Opin Investig Drugs; 2007 Jul; 8(7):531-8. PubMed ID: 17659473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dosing of atypical antipsychotics.
    de Leon J; Armstrong SC; Cozza KL
    Psychosomatics; 2005; 46(3):262-73. PubMed ID: 15883149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.
    Mauri MC; Volonteri LS; Colasanti A; Fiorentini A; De Gaspari IF; Bareggi SR
    Clin Pharmacokinet; 2007; 46(5):359-88. PubMed ID: 17465637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 polymorphisms and response to antipsychotic therapy.
    Scordo MG; Spina E
    Pharmacogenomics; 2002 Mar; 3(2):201-18. PubMed ID: 11972442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.
    Spina E; Perucca E
    Epilepsia; 2002; 43 Suppl 2():37-44. PubMed ID: 11903482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP-mediated clozapine interactions: how predictable are they?
    Chetty M; Murray M
    Curr Drug Metab; 2007 May; 8(4):307-13. PubMed ID: 17504220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions and antipsychotic therapy.
    DeVane CL
    Pharmacotherapy; 1996; 16(1 Pt 2):15-20. PubMed ID: 8778682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
    Beunk L; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Risselada A; Rongen GAPJM; van Schaik RHN; Swen JJ; Touw D; van Westrhenen R; Deneer VHM; van der Weide J
    Eur J Hum Genet; 2024 Mar; 32(3):278-285. PubMed ID: 37002327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients.
    Conley RR; Kelly DL
    Psychopharmacol Bull; 2007; 40(1):77-97. PubMed ID: 17285099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.